Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ADHD In Japan Starting To Find An Easier Regulatory Path; Shire Advances Pipeline

This article was originally published in PharmAsia News

Executive Summary

Shire recently initiated a Phase II/III study for Intuniv, and Vyvanse is not far behind. Currently only two products are approved for ADHD in Japan.

You may also be interested in...

Ranbaxy’s GMP Woes Puts Spotlight On Daiichi Sankyo Due Diligence

Whether Daiichi Sankyo will be able to claim damages from Ranbaxy’s former owners will depend on what Daiichi Sankyo knew before the acquisition, and its chances of proving misrepresentation may be slim.

Are Novartis’ Advertising Charges In Japan The Tip Of The Iceberg?

Prosecutors are looking into allegations of exaggerated advertising, but a bribery investigation may be the real aim for authorities.

HIV Treatment Options For Patients Improve In Japan

Japan Tobacco brings Stribild home after U.S./EU launches by Gilead. Johnson & Johnson reduces patient burden with higher dose Prezista.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts